IL137353A0 - New salt forms of (2e) -5- amino-5-methylhex -2- enoic acid n-methyl -n- ((1r) -1-(n-methyl -n- ((1r) -1-(methylcarbamoyl) -2- phenylethyl) carbamoyl)-2-(2-naphthyl)ethyl)amid - Google Patents

New salt forms of (2e) -5- amino-5-methylhex -2- enoic acid n-methyl -n- ((1r) -1-(n-methyl -n- ((1r) -1-(methylcarbamoyl) -2- phenylethyl) carbamoyl)-2-(2-naphthyl)ethyl)amid

Info

Publication number
IL137353A0
IL137353A0 IL13735399A IL13735399A IL137353A0 IL 137353 A0 IL137353 A0 IL 137353A0 IL 13735399 A IL13735399 A IL 13735399A IL 13735399 A IL13735399 A IL 13735399A IL 137353 A0 IL137353 A0 IL 137353A0
Authority
IL
Israel
Prior art keywords
methyl
methylcarbamoyl
phenylethyl
carbamoyl
naphthyl
Prior art date
Application number
IL13735399A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL137353A0 publication Critical patent/IL137353A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/60Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL13735399A 1998-03-03 1999-02-26 New salt forms of (2e) -5- amino-5-methylhex -2- enoic acid n-methyl -n- ((1r) -1-(n-methyl -n- ((1r) -1-(methylcarbamoyl) -2- phenylethyl) carbamoyl)-2-(2-naphthyl)ethyl)amid IL137353A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK28298 1998-03-03
PCT/DK1999/000089 WO1999045029A1 (en) 1998-03-03 1999-02-26 New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphtyl)ethyl)amide

Publications (1)

Publication Number Publication Date
IL137353A0 true IL137353A0 (en) 2001-07-24

Family

ID=8091813

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13735399A IL137353A0 (en) 1998-03-03 1999-02-26 New salt forms of (2e) -5- amino-5-methylhex -2- enoic acid n-methyl -n- ((1r) -1-(n-methyl -n- ((1r) -1-(methylcarbamoyl) -2- phenylethyl) carbamoyl)-2-(2-naphthyl)ethyl)amid

Country Status (15)

Country Link
EP (1) EP1060190B1 (zh)
JP (1) JP2002505340A (zh)
KR (1) KR20010041533A (zh)
CN (1) CN1291994A (zh)
AT (1) ATE254632T1 (zh)
AU (1) AU3247899A (zh)
BR (1) BR9908399A (zh)
CA (1) CA2322051A1 (zh)
DE (1) DE69912930D1 (zh)
HU (1) HUP0100998A3 (zh)
IL (1) IL137353A0 (zh)
PL (1) PL342706A1 (zh)
TW (1) TW538047B (zh)
WO (1) WO1999045029A1 (zh)
ZA (1) ZA991572B (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
US10023600B2 (en) 2009-09-21 2018-07-17 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
EP2805960A1 (en) 2010-07-19 2014-11-26 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
CA2972592A1 (en) 2015-01-08 2016-07-14 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
BR112018005048B8 (pt) 2015-09-16 2021-03-23 Gilead Sciences Inc uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae
AU2018235754B2 (en) 2017-03-14 2021-04-08 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
CN118766947A (zh) 2020-01-27 2024-10-15 吉利德科学公司 用于治疗SARS CoV-2感染的方法
WO2021183750A2 (en) 2020-03-12 2021-09-16 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
KR20220164784A (ko) 2020-04-06 2022-12-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
CN115666570A (zh) 2020-05-29 2023-01-31 吉利德科学公司 瑞德西韦治疗方法
EP4172160A2 (en) 2020-06-24 2023-05-03 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
CA3190702A1 (en) 2020-08-27 2022-03-03 Elaine Bunyan Compounds and methods for treatment of viral infections
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2323159T3 (es) * 1995-12-22 2009-07-07 Novo Nordisk A/S Compuestos con propiedades de liberacion de la hormona del crecimiento.

Also Published As

Publication number Publication date
WO1999045029A1 (en) 1999-09-10
CN1291994A (zh) 2001-04-18
HUP0100998A3 (en) 2001-12-28
JP2002505340A (ja) 2002-02-19
EP1060190A1 (en) 2000-12-20
ATE254632T1 (de) 2003-12-15
EP1060190B1 (en) 2003-11-19
PL342706A1 (en) 2001-07-02
HUP0100998A2 (hu) 2001-08-28
DE69912930D1 (de) 2003-12-24
TW538047B (en) 2003-06-21
KR20010041533A (ko) 2001-05-25
BR9908399A (pt) 2000-10-31
AU3247899A (en) 1999-09-20
ZA991572B (en) 1999-09-03
CA2322051A1 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
IL137353A0 (en) New salt forms of (2e) -5- amino-5-methylhex -2- enoic acid n-methyl -n- ((1r) -1-(n-methyl -n- ((1r) -1-(methylcarbamoyl) -2- phenylethyl) carbamoyl)-2-(2-naphthyl)ethyl)amid
RS82003A (en) Anthranilic acid amides, method for the production thereof, their use as antiarhythmia agents, and pharmaceutical preparations thereof
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
AU2003245804A1 (en) Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
MY138220A (en) ARYL ANILINE ß2 ADRENERGIC RECEPTOR AGONISTS
EP1961748A3 (en) 2-Hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors
WO2004043363A8 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
IL145429A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
MXPA02002249A (es) Composiciones farmaceuticas agradables al paladar para animales de compania.
HK1066539A1 (en) Ortho-substituted nitrogen-containing bisaryl compounds use as potassium channel inhibitors
IN2005KO00312A (zh)
NO20061575L (no) Fremgangsmate for fremstilling av renzapride og mellomprodukter derav
EP0981352B8 (en) Use of aplidine for the treatment of cardiovascular diseases
WO2002057215A3 (en) Sodium channel modulators
AU2001267886A1 (en) Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
TW200420557A (en) Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
TW324662B (en) Benzamide-containing pharmaceutical composition
MXPA03009984A (es) PREPARACION PARA LA REMOCIoN DE MATERIAL QUERATINOSO ANORMAL.
UA83268C2 (en) Insecticidal agent
MY120237A (en) Method for the synthesis of quinoline derivatives
AU2003267360A1 (en) Hair treatment agent containing an active combination of liposomes
WO2003017762A3 (de) Fungizide wirkstoffkombinationen